The Cooper Companies, Inc. $COO Stock Position Reduced by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board has reduced its stake in The Cooper Companies, Inc. by 45.9% in the first quarter, now holding 107,766 shares worth approximately $9.09 million.
• Despite the reduction in its holdings, several other institutional investors have increased their stakes in The Cooper Companies, including Shell Asset Management Co. and UMB Bank n.a., indicating ongoing interest in the company.
• The Cooper Companies reported earnings of $1.10 per share, exceeding estimates, and also projected a fiscal year 2025 EPS guidance of 4.080-4.120, reflecting growth prospects.

Canada Pension Plan Investment Board reduced its holdings in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 45.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,766 shares of the medical device company's stock after selling 91,404 shares during the quarter. Canada Pension Plan Investment Board owned approximately 0.05% of Cooper Companies worth $9,090,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in COO. Zions Bancorporation National Association UT acquired a new stake in Cooper Companies during the first quarter worth about $33,000. City Holding Co. acquired a new stake in Cooper Companies during the first quarter worth about $34,000. GKV Capital Management Co. Inc. acquired a new stake in Cooper Companies during the first quarter worth about $40,000. Larson Financial Group LLC increased its stake in Cooper Companies by 1,071.0% during the first quarter. Larson Financial Group LLC now owns 726 shares of the medical device company's stock worth $61,000 after acquiring an additional 664 shares during the last quarter. Finally, HM Payson & Co. increased its stake in Cooper Companies by 147.4% during the first quarter. HM Payson & Co. now owns 893 shares of the medical device company's stock worth $75,000 after acquiring an additional 532 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

COO has been the subject of several research analyst reports. Mizuho dropped their price target on Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. Needham & Company LLC restated a "buy" rating and set a $94.00 price target on shares of Cooper Companies in a research note on Thursday, August 28th. Wall Street Zen lowered Cooper Companies from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. BNP Paribas Exane raised Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 target price for the company in a research report on Tuesday, July 22nd. Finally, BNP Paribas raised Cooper Companies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Cooper Companies currently has an average rating of "Moderate Buy" and an average price target of $86.64.

Insiders Place Their Bets

In other Cooper Companies news, COO Gerard H. Warner III purchased 1,450 shares of Cooper Companies stock in a transaction that occurred on Friday, September 5th. The stock was purchased at an average price of $69.23 per share, with a total value of $100,383.50. Following the completion of the acquisition, the chief operating officer owned 18,319 shares of the company's stock, valued at approximately $1,268,224.37. This trade represents a 8.60% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Albert G. White III purchased 10,000 shares of Cooper Companies stock in a transaction that occurred on Friday, September 5th. The stock was acquired at an average cost of $68.39 per share, with a total value of $683,900.00. Following the acquisition, the chief executive officer directly owned 226,151 shares of the company's stock, valued at $15,466,466.89. The trade was a 4.63% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders bought 15,975 shares of company stock worth $1,079,566. Company insiders own 1.98% of the company's stock.

Cooper Companies Stock Up 0.1%

Shares of NASDAQ COO traded up $0.09 on Friday, hitting $68.09. The company had a trading volume of 2,759,386 shares, compared to its average volume of 2,951,187. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $112.38. The business has a 50 day moving average of $71.99 and a two-hundred day moving average of $76.65. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $13.54 billion, a P/E ratio of 33.54, a PEG ratio of 1.72 and a beta of 0.97.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.03. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.Cooper Companies's revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.